Get 20% Free Customization In This Report

Buy this report from - $3456

Hypercholesterolemia Drugs Market by Product (Statins and Non-statins) and by Application (HMG-CoA Reductase Inhibitors, Fibric Acid Derivatives, Bile Acid Sequestrants, and Others) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Healthcare	LI_183676	Pages: NA	Jun 2018 \| 601 Views
Author's : NA	Tables: NA	Charts: NA	Formats*:

Hypercholesterolemia is a condition caused by presence of high amounts of cholesterol in the blood. It can be caused by unhealthy diet intake, obesity or because of incidence of other diseases such as diabetes and an underacti e thyroid, in some cases its hereditary. The condition can be life threating if not treated, hence anti-hyperlipidemic drugs are utilized to keep the condition in check and to a oid further health complication such as heart attack.

Increase in pre alence of heart disorders and unhealthy eating habits leading to obesity are expected to dri e the hypercholesterolemia drugs market. Technological ad ancement in drugs and surge in supply channels boost the market growth. Howe er, alternati e medications and increase in awareness among populace regarding fitness and health obstructs the market growth.

The global hypercholesterolemia drugs market is segmented on the basis of product, application, and geography. On the basis of product, the market is di ided into statins and non-statins. By application, the market is classified into HMG-CoA reductase inhibitors, fibric acid deri ati es, bile acid sequestrants, and others. By geography, it is analyzed across North America, Europe, Asia Pacific, and LAMEA.

Comprehensi e competiti e analysis and profiles of major market players such as AstraZeneca, Merck, Pfizer, Aegerion Pharmaceuticals, Abb ie, Sanofi, Alnylam Pharmaceuticals, Amarin Corporation, Amgen, AtheroNo a are pro ided in this report.

Key Benefits

The study pro ides an in-depth analysis of the market along with current trends and future estimations to elucidate the imminent in estment pockets.
Extensi e analysis of the market is conducted by following key product positioning and monitoring the top competitors within the market framework
It offers a quantitati e analysis from 2017 to 2023 to enable the stakeholders to capitalize on the pre ailing market opportunities.
Comprehensi e analysis of all geographical regions is pro ided to determine the pre ailing opportunities.
Key players are profiled and their strategies are analyzed thoroughly to understand the competiti e outlook of the global market.

Hypercholesterolemia Drugs Market Key Segments:

By Product

Statins
Non-statins

By Application

HMG-CoA Reductase Inhibitors
Fibric Acid Deri ati es
Bile Acid Sequestrants
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Taiwan
- Rest of Asia-Pacific
LAMEA
- Brazil
- Turkey
- Saudi Arabia
- South Africa
- Rest of LAMEA

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS

3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities

Chapter: 4 GLOBAL VITAMIN K3 MARKET, BY PRODUCT

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. STATINS

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. NON-STATINS

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

Chapter: 5 GLOBAL VITAMIN K3 MARKET, BY APPLICATION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. HMG-COA REDUCTASE INHIBITORS

5.2.1. Market size and forecast

5.3. FIBRIC ACID DERIVATIVES

5.3.1. Market size and forecast

5.4. BILE ACID SEQUESTRANTS

5.4.1. Market size and forecast

5.5. OTHERS

5.5.1. Market size and forecast

Chapter: 6 VITAMIN K3 MARKET, BY GEOGRAPHY

6.1. OVERVIEW
6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast

6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast

6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Italy market size and forecast
6.3.3.5. Spain market size and forecast
6.3.3.6. Rest of Europe market size and forecast

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast

6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. Australia market size and forecast
6.4.3.4. India market size and forecast
6.4.3.5. South Korea market size and forecast
6.4.3.6. Taiwan market size and forecast
6.4.3.7. Rest of Asia-Pacific market size and forecast

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast

6.5.3.1. Brazil market size and forecast
6.5.3.2. Turkey market size and forecast
6.5.3.3. Saudi Arabia market size and forecast
6.5.3.4. South Africa market size and forecast
6.5.3.5. Rest of LAMEA market size and forecast

Chapter: 7 COMPANY PROFILES

7.1. ASTRAZENECA

7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments

7.2. MERCK

7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments

7.3. PFIZER

7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments

7.4. AEGERION PHARMACEUTICALS

7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments

7.5. ABBVIE

7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments

7.6. SANOFI

7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments

7.7. ALNYLAM PHARMACEUTICALS

7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments

7.8. AMARIN CORPORATION

7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments

7.9. AMGEN

7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments

7.10. ATHERONOVA

7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.